Abstract:While the term artificial intelligence and the concept of deep learning are not new, recent advances in high-performance computing, the availability of large annotated data sets required for training, and novel frameworks for implementing deep neural networks have led to an unprecedented acceleration of the field of molecular (network) biology and pharmacogenomics. The need to align biological data to innovative machine learning has stimulated developments in both data integration (fusion) and knowledge representation, in the form of heterogeneous, multiplex, and biological networks or graphs. In this chapter we briefly introduce several popular neural network architectures used in deep learning, namely, the fully connected deep neural network, recurrent neural network, convolutional neural network, and the autoencoder. Deep learning predictors, classifiers, and generators utilized in modern feature extraction may well assist interpretability and thus imbue AI tools with increased explication, potentially adding insights and advancements in novel chemistry and biology discovery.The capability of learning representations from structures directly without using any predefined structure descriptor is an important feature distinguishing deep learning from other machine learning methods and makes the traditional feature selection and reduction procedures unnecessary. In this chapter we briefly show how these technologies are applied for data integration (fusion) and analysis in drug discovery research covering these areas: (1) application of convolutional neural networks to predict ligand–protein interactions; (2) application of deep learning in compound property and activity prediction; (3) de novo design through deep learning. We also: (1) discuss some aspects of future development of deep learning in drug discovery/chemistry; (2) provide references to published information; (3) provide recently advocated recommendations on using artificial intelligence and deep learning in -omics research and drug discovery.

Towards a Machine-Learning-Based Application for Amorphous Drug Recognition

Machine Learning for Analyzing Atomic Force Microscopy (AFM) Images Generated from Polymer Blends

Machine Learning Approaches and their Applications in Drug Discovery and Design

Structural characterisation of amorphous solid dispersions via metropolis matrix factorisation of pair distribution function data

Applications of Machine Learning in Computer-Aided Drug Discovery

Novel Big Data-Driven Machine Learning Models for Drug Discovery Application

Data Integration Using Advances in Machine Learning in Drug Discovery and Molecular Biology

Integrated analysis of X-ray diffraction patterns and pair distribution functions for machine-learned phase identification

Deep learning for automated classification and characterization of amorphous materials

Machine learning directed drug formulation development

The essential synergy of MD simulation and NMR in understanding amorphous drug forms

Application advances of deep learning methods for de novo drug design and molecular dynamics simulation

Crystal Structure Assignment for Unknown Compounds from X-ray Diffraction Patterns with Deep Learning

Crystal Structure Assignment for Unknown Compounds from X-ray Diffraction Patterns with Deep Learning.

Adaptively driven X-ray diffraction guided by machine learning for autonomous phase identification

Machine learning classification of local environments in molecular crystals

Machine learning in drug delivery

Advances in De Novo Drug Design: From Conventional to Machine Learning Methods

Machine Learning Harnesses Molecular Dynamics to Discover New $μ$ Opioid Chemotypes

Near-Term Quantum Classification Algorithms Applied to Antimalarial Drug Discovery

The emergence of machine learning force fields in drug design